Author:
Palmerini Emanuela,Peta Giuliano,Tuzzato Gianmarco
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Palmerini E, Longhi A, Donati DM, Staals EL. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. Expert Rev Anticancer Ther. 2020;20:441–5.
2. Healey JH, Bernthal NM, van de Sande M. Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease. J Am Acad Orthop Surg Glob Res Rev. 2020;4(e20):00028.
3. Vaynrub A, Healey JH, Tap W, Vaynrub M. Pexidartinib in the management of advanced tenosynovial giant cell tumor: focus on patient selection and special considerations. Onco Targets Ther. 2022;15:53–66.
4. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006;103:690–5.
5. Fang H, He R, Chiu A, et al. Genetic factors in acute myeloid leukemia with myelodysplasia-related changes. Am J Clin Pathol. 2020;153:656–63.